SCHEDULE 13G/A: T. Rowe Price Boosts Stake in Applied Therapeutics to 13.2%

T. Rowe Price Investment Management, Inc. has reported a significant beneficial ownership stake of 13.2% in Applied Therapeutics Inc., holding 18,683,990 shares.

Summary

• T. Rowe Price Investment Management, Inc. (TRPIM) filed an Amendment No. 2 to Schedule 13G for Applied Therapeutics Inc.
• TRPIM beneficially owns 18,683,990 shares of Applied Therapeutics Inc. common stock.
• This ownership represents 13.2% of the total class of securities.
• TRPIM holds sole voting power and sole dispositive power over all 18,683,990 shares.
• T. ROWE PRICE SMALL-CAP VALUE FUND, advised by TRPIM, holds 11,470,668 shares, representing 8.1% of the class.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant and continued institutional investment by T. Rowe Price, a reputable asset manager, in Applied Therapeutics Inc. A 13.2% stake suggests a strong conviction in the company's prospects, which is generally a positive signal for other investors.

Positives

• A major institutional investor, T. Rowe Price Investment Management, Inc., holds a significant stake of 13.2% in Applied Therapeutics Inc., indicating confidence in the company.
• The T. Rowe Price Small-Cap Value Fund, a specific fund managed by T. Rowe Price, holds 8.1% of the class, further demonstrating targeted investment.

Future Outlook

NA

Industry Context

The filing indicates a significant institutional investment in Applied Therapeutics Inc. Such substantial stakes by reputable investment firms like T. Rowe Price can signal perceived value or growth potential, potentially attracting further investor interest in the company.

Stakeholder Impact

• Shareholders: The significant stake held by T. Rowe Price may instill confidence and potentially attract other institutional or retail investors, positively impacting share price stability and liquidity.
• Company Management: A large institutional holder like T. Rowe Price can exert influence through voting power, potentially aligning management decisions with long-term shareholder value.

Key Dates

Recommendation

The disclosure of a substantial 13.2% beneficial ownership by T. Rowe Price Investment Management, Inc. in Applied Therapeutics Inc. is a positive signal, indicating institutional confidence. However, a Schedule 13G filing primarily reports ownership and does not provide operational or financial performance details. Therefore, while the institutional backing is favorable, a 'hold' recommendation is appropriate, advising investors to conduct further due diligence on the company's fundamentals before making a definitive investment decision.

Keywords

Applied Therapeutics Inc., T. Rowe Price Investment Management, Schedule 13G, beneficial ownership, institutional investor, common stock, investment adviser, equity stake